KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Assets Average: 2009-2025

Historic Assets Average for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Sep 2025 value amounting to $7.5 billion.

  • Biomarin Pharmaceutical's Assets Average rose 8.28% to $7.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 billion, marking a year-over-year increase of 8.28%. This contributed to the annual value of $6.9 billion for FY2024, which is 4.64% up from last year.
  • Biomarin Pharmaceutical's Assets Average amounted to $7.5 billion in Q3 2025, which was up 3.20% from $7.3 billion recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Assets Average registered a high of $7.5 billion during Q3 2025, and its lowest value of $5.8 billion during Q1 2021.
  • In the last 3 years, Biomarin Pharmaceutical's Assets Average had a median value of $6.9 billion in 2024 and averaged $6.9 billion.
  • Data for Biomarin Pharmaceutical's Assets Average shows a peak YoY increase of 23.80% (in 2021) and a maximum YoY decrease of 0.20% (in 2021) over the last 5 years.
  • Over the past 5 years, Biomarin Pharmaceutical's Assets Average (Quarterly) stood at $6.0 billion in 2021, then rose by 5.48% to $6.3 billion in 2022, then rose by 7.60% to $6.8 billion in 2023, then increased by 1.77% to $6.9 billion in 2024, then climbed by 8.28% to $7.5 billion in 2025.
  • Its Assets Average stands at $7.5 billion for Q3 2025, versus $7.3 billion for Q2 2025 and $7.1 billion for Q1 2025.